These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31471165)

  • 21. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
    Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA
    Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
    Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
    J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New drugs: Ceftaroline fosamil, pegloticase, and eribulin mesylate.
    Hussar DA; Pasco L
    J Am Pharm Assoc (2003); 2011; 51(2):316-9. PubMed ID: 21382815
    [No Abstract]   [Full Text] [Related]  

  • 26. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a multivariable improvement measure for gout.
    Schlesinger N; Edwards NL; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic perspectives on uricases for gout.
    Garay RP; El-Gewely MR; Labaune JP; Richette P
    Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series.
    Botson JK; Peterson J
    J Clin Rheumatol; 2022 Jan; 28(1):e129-e134. PubMed ID: 33044389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    Pillinger MH; Fields TR; Yeo AE; Lipsky PE
    J Rheumatol; 2020 Apr; 47(4):605-612. PubMed ID: 31203212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
    Freyne B
    Transplant Proc; 2018 Dec; 50(10):4099-4101. PubMed ID: 30577324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New trend in gout treatment. Clinical and biological study of urate oxidase].
    Mizon JP; Plaquet R; Gentit F; Quiret JC
    Lille Med; 1971 Nov; 16(9):1332-45. PubMed ID: 4945000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.